Cell‐Free Fetal DNA Screening for Chromosomal Anomalies: Green‐Top Guideline No. 77
Cell-Free Fetal DNA Testing for Chromosomal Conditions (T21, T18, T13)• Cell-free fetal DNA (cffDNA) testing can be safely and feasibly offered to women either as a first line screening test in unselected populations, or within a contingent model for the accurate identification of fetuses with trisomies 21, 18 and 13 (T21, T18 and T13).[Grade A]• In the setting of raised nuchal translucency (3.5mm or greater) or the finding of a fetal anomaly, women should be referred to a fetal medicine unit and, where indicated, offered invasive diagnostic testing.In a setting where invasive testing has been declined, cffDNA testing may be offered.[Grade A]• For women who have a higher chance for T21, T18 or T13 due to a previous affected pregnancy, cffDNA testing should be offered as a first line screening test.[GPP]• Pregnant women must be informed that cffDNA testing is a form of prenatal screening as opposed to a diagnostic test.[Grade A]• In test failure due to low cffDNA fetal fraction, the presence of T18 and T13 should be considered.[Grade B]• When cffDNA fails to yield a result, a detailed review of the woman's initial a priori chance and indications for cffDNA testing should be undertaken.[GPP] • Women who want to avoid a diagnostic test and would wish to continue a pregnancy with T21, T18 or T13, may still value the information a cffDNA test can give them.This is a valid choice and must be respected.[GPP] Expanding the Use of cffDNA Testing Beyond the Detection of T21, T18 and T13• cffDNA testing for detection of copy number variants is not currently recommended.[Grade B]• cffDNA testing for rare autosomal trisomies (RATs) is not currently recommended.[Grade B] cffDNA Testing in the Setting of Multiple Pregnancy• cffDNA testing may be offered to women with a twin pregnancy.[Grade A]• There is a higher chance of a false positive result with a vanishing twin, and therefore cffDNA testing in the presence of a vanishing twin is not recommended.[Grade C]• cffDNA testing cannot currently be recommended for aneuploidy screening in triplet or higher order multiple pregnancy.[Grade D]
Authors
- Surabhi Nanda (ORCID: https://orcid.org/0000-0003-3955-1304)
- Fionnuala Mone (ORCID: https://orcid.org/0000-0002-0718-7547)
- Aris T. Papageorghiou (ORCID: https://orcid.org/0000-0001-8143-2232)
- Kypros H. Nicolaides (ORCID: https://orcid.org/0000-0003-1266-0711)
- Mark David Kilby (ORCID: https://orcid.org/0000-0001-9987-4223)
- Jane Fisher (ORCID: https://orcid.org/0000-0003-1318-0074)
- Pranav Pandya
- Jehan Karim
Institutions
- Royal College of Obstetricians and Gynaecologists (GB)
Publication Details
- Journal
- BJOG An International Journal of Obstetrics & Gynaecology
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1111/1471-0528.70337
- Primary Topic
- Prenatal Screening and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Public Health Wales
- University of Oxford
- Kementerian Pendidikan Nasional